Press Release:
Novo Nordisk launches new insulin product
Mexican healthcare system to receive next-generation insulin, Tresiba®
Mexico City, Tuesday 18th of February, 2014
Tresiba® the next-generation insulin has been launched in Mexico. It has already been launched in Switzerland, Japan and Europe making Mexico an addition to the market. Tresiba® is a new insulin product developed for people suffering from type 1 or type 2 diabetes. It allows the patients more flexibility with the injection process. Tresiba® allows them to administer the shot once every 24 hours rather than multiple times daily. It is also available in FlexTouch, which is a pre-filled pen with a touch button, making it easier for individuals to administer the shot.
Tresiba® is backed by extensive testing conducted on over 1600 patients in three different trials. It has also shown to cause reduction in weight as well as lower rate of hypoglycaemia, when using the hybrid product, IDegLira. This hybrid is a combination of Tresiba® and the obesity and pre-diabetes product Victoza®. Officials hope that with this new medicine will help the country that suffers with over 10 million people with diabetes and a high death rate each year from the disease.
In addition, Novo is negotiating with the FDA to start clinical trial protocol for the cardiovascular outcome of Tresiba® on the U.S. market and have high expectations according to Lars Rebien Sørensen, President & CEO of Novo Nordisk:
“We expect to start the trial before the end of the year in the U.S. based on the positive feedback from the FDA regarding the design of the cardiovascular outcomes trials for Tresiba®.“
For further details, please contact:
Press spokesman, Lars Anderesen
+45 8888 8888
aaaa@novonordisk.com
Target group: Mexicans public/diabetics
Media: “Diabetes Hoy” by the Federación Mexicana de Diabetes (“Diabetes Today” - magazine by Mexican Diabetes Federation) + El Informador (http://www.informador.com.mx/) - mexican newspaper.
SEO:
Author Andrew Smith, once said, “People fear what they don't understand and hate what they can't conquer.”So the key to awareness is education. If society are more educated about the disease, diabetics will feel less discriminated and be able to feel a part of their communities.
“Shame on you, diabetic”
One out of five diabetics feel discriminated in their daily life.
Keywords
Diabetes 1 & 2 / Discrimination / Sickness / Obesity / Disgusting / Problems / Conflict / Frustration / Self-confident / Self-esteem
Health-care / Attitudes / Acceptance / DAWN2 / ADA / NOVO Nordisk / IDF / The International alliance of patients organisations / IAPO / The Steno Diabetes Center awareness / Depression / America / Medication / Jobs
Tools: Übersuggest.org
Media: Blog
The most common type of diabetic discrimination is in fact unawareness and misunderstanding of diabetes from neighbours and community members. This unawareness can lead to diabetics being prevented from taking checking their blood levels, eat and taking insulin.
At the annual meeting of the American Diabetes Association (ADA) held in Chicago DAWN2 (Diabetes Attitudes Wishes and Needs) presented some of their results regarding people suffering from Diabetes type 1 and 2. The initial results shows that one in five feel discriminated because of diabetes either in their work- or private life. They feel discriminated because of their condition and perceive support from the broader community as scarce.
“Some of the most common types of discrimination involve barriers to diabetes management, as well as a fair amount of ignorance about diabetes. A lot of discrimination may happen because employers do not understand diabetes, or they do not recognize how diabetes affects a particular employee.”
Katie Hathaway, head of Legal Advocacy for the American Diabetes Association
DAWN2™ is a global Novo Nordisk initiative conducted in collaboration with the IDF, the International Alliance of Patient Organisations (IAPO), the Steno Diabetes Center and a range of other national, regional and global partners.
DAWN2 interviewed 15,000 people with both diabetes 1 and 2, in 17 countries in 2011. The study shows that families of adults with diabetes face challenges within the area of self-management, adherence, access to support and involvement in care. DAWN2’s purpose is to create understanding, awareness and inspire new ways to enable people with diabetes to live a comprehensive life, where they are able to manage their own quality of life.
The discrimination is also concerning the health care professionals where one out of three expressed a ´major need´ for improvement in the acceptance of the people with diabetes as equal members in society.
According to DAWN2, there are more than 371 million people that have diabetes in the world’s adult population in 2012. They are expecting that this number will increase to 552 million by 2030. Some of these people are affected in their daily lives by discrimination from their communities.
Also, DAWN2™ study results released during ADA highlighted significant inadequacies across countries in relation to empowerment and education of people with diabetes, psychosocial support and quality diabetes care.
In addition to feeling discriminated, there have been reports that people living with diabetes cause a significant burden on their family members. This could add to the cause that 44.6% of diabetics in the United States, the Netherlands and Algeria have had emotional distress relating to the disease.
Author Andrew Smith, once said, “People fear what they don't understand and hate what they can't conquer.”So the key to awareness is education. If society are more educated about the disease, diabetics will feel less discriminated and be able to feel a part of their communities.
